Audio
In this episode of “Conversations with Dr. Brian Durie,” Dr. Durie is joined by Dr. Suzanne Lentzsch of the New York-Presbyterian Hospital, and IMF Board Member and myeloma patient Yelak Biru. Listen as Dr. Suzanne Lentzsch describes her experience working on the front lines of the COVID-19…
News Article
The entire International Myeloma Foundation team is saddened by the passing of our very dear friend Fred Willard.
Through the years, Fred performed at the IMF's Annual Comedy Celebration. We are forever grateful for the countless volunteer performances he gave to his fans at our largest…
Audio
Hosted by Dr. Brian G.M. Durie, world-renowned myeloma expert and Chairman of the Board of the International Myeloma Foundation, the "Conversations with Dr. Durie" podcast focuses on inspirational and educational topics that are relevant to the myeloma community and beyond.
In this episode, Dr.…
Audio
The “A Day in the Life” podcast from the International Myeloma Foundation (IMF) features messages of hope and resilience for myeloma patients, caregivers, and their loved ones.
In Memoriam: We recorded the following interview with Mark Ho on April 17, 2020. Unfortunately,…
Page
Brief Overview: The Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 was the first piece of legislation passed to address COVID-19. This bill was an emergency supplemental appropriations bill (spending bill) that can be viewed…
Page
Food and Nutrition Services Safety Net Programs
FY2020 supplemental appropriations to the Department of Agriculture (USDA) for nutrition and food assistance programs, including:
The Special Supplemental Nutrition Program for Women, infants, and Children (WIC…
Page
Brief Summary: The Corona Virus Aid, Relief, and Economic Security Act (CARES) Act was signed into law on March 27, 2020. The bill provides financial relief for the American public and American businesses while also providing additional public health funding to combat the virus.…
Page
Defense Production Act
On March 20th, President Trump stated he had invoked his emergency war powers under the Defense Production Act to direct private businesses to produce and distribute medical supplies in anticipation of a surge in demand. As of April 16th, it is our understanding that the…
Videos
In this week’s video, Dr. Durie discusses what options myeloma patients have when drug side effects impact their quality of life.
BOTTOM LINE:
Discuss treatment changes carefully with your doctor.
Transcript:
This week's “Ask Dr. Durie” comes from a…
News Article
To the Myeloma Community,
We wanted to take some time and to keep you up to date on the Federal Government’s response regarding COVID-19. We have received a lot of questions from patients and their families about what is included in the response, and what the government has done…
News Article
The International Myeloma Foundation is very pleased to announce that Martine Elias has joined the IMF Board of Directors. Martine brings tremendous experience and commitment to the Board, and the IMF looks forward to her active involvement in our many programs.
Martine Elias is the…
Page
Get the Latest Information on COVID-19 for Myeloma Patients
Know your COVID-19 Community Level, read up on the IMF's latest recommendations and answers to FAQs on COVID-19 vaccines, boosters, anti-viral treatments, and more.
News Article
Given the growing concerns over the COVID-19 (coronavirus) outbreak, the International Myeloma Foundation wants you to know our plans to ensure your access to our resources.
With a focus on the health and well-being of our staff, the IMF’s physical offices will close on…
News Article
The randomized phase III BOSTON study evaluates “once-weekly XPOVIO® (selinexor) in combination with once-weekly Velcade® (bortezomib) and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade plus low-dose dexamethasone (Vd) in patients with multiple myeloma who have received one…
News Article
The International Myeloma Foundation is very pleased that Sarclisa (isatuximab-irfc), a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells, has just been approved by the FDA.This approval means patients with relapsed/refractory multiple myeloma (RRMM) who have received at…
News Article
The International Myeloma Foundation (IMF) is harnessing the power of multiple myeloma patients, their families, and the community at large to raise awareness of the blood cancer during Myeloma Action Month (MAM), starting March 1, 2020. The organization commemorates its 30-year anniversary this…
Videos
In this week’s video, Dr. Durie discusses if bone fractures resulting from an accident, such as a fall, could indicate disease progression, and what measures should be…
IMF Person
Associate Director, Myeloma Translational Research
The Mount Sinai Health System
New York, NY
IMF Person
With over 7 years of experience in marketing and communications, I am currently leading the development and execution of effective marketing and communications strategies at the International Myeloma Foundation (IMF), a nonprofit organization dedicated to improving the lives of people affected by…
Videos
In this week’s video, Dr. Durie discusses if various infections could trigger onset myeloma.BOTTOM LINE:The link between infections and the…
Event
This hour-long workout will begin with a series of seated warm up stretches focusing on the breath. A fusion of standing tai chi patterns and yoga poses will follow. Guided meditation will conclude the workout.
Videos
In this week’s video, Dr. Durie discusses if Fluorescence in Situ Hybridization (FISH) testing should be done at relapse. BOTTOM LINE:Yes, FISH testing should be performed at relapse. Transcript:This week’s “Ask Dr. Durie” is from a patient asking a question about…
News Article
The International Myeloma Foundation announces the launch of a new program created in partnership with Medscape Oncology that offers healthcare professionals an opportunity to earn continuing medical education (CME) credit. "…
News Article
Dr. Durie has written often about the "Blue Zones" that author Dan Buettner noted in his 2005 National Geographic cover article, "Secrets of a Long Life." These Blue Zones are regions of the world where people live much longer than average. Here's what people who live in Blue Zones do—a list of…
Videos
In this week’s video, Dr. Durie discusses if emerging immune therapies such as CAR T cells, and BiTEs, can replace the need for autologous stem cell transplant (ASCT).BOTTOM LINE:ASCT treatment is the current standard of care for patients under the age of 65. Transcript:…
Videos
Introduction: The GEM-CESAR trial is a potentially curative strategy for high-risk smoldering multiple myeloma (HRsMM) patients in which the primary endpoint is the assessment of bone marrow minimal residual disease negativity by next generation flow (NGF). However, alternative…
Videos
Introduction: Daratumumab, a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action, is approved in combination with standard-of-care regimens for the treatment of newly diagnosed multiple myeloma (NDMM) and RRMM. …
Page
For more than a decade, the International Myeloma Foundation has attended the American Society of Hematology (ASH) annual meeting, an exciting convergence of more than 30,000 health-care professionals from around the world. This year’s ASH annual meeting took place in Orlando, Florida, from Dec. 7-…
Videos
Introduction: Chimeric antigen receptor (CAR) T cell therapy directed against B cell maturation antigen (BCMA) has shown promising results for the treatment of relapsed refractory multiple myeloma (RRMM) in several phase 1 studies. Persistence of CAR T cells post infusion may be…
Videos
Estrategia curativa (GEM-CESAR) para el mieloma latente de alto riesgo (SMM): Carfilzomib, lenalidomida y Dexametasona (KRd) como inducción Seguido por HDT-ASCT, Consolidación con Krd y Mantenimiento con Rd
Introduction: SMM is an asymptomatic and heterogeneous plasma cell…
Videos
Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
Introduction: SMM is an asymptomatic and heterogeneous plasma cell…
Videos
Background: Venetoclax (Ven) is a selective, small molecule inhibitor of anti-apoptosis protein Bcl-2 that has antitumoral activity against multiple myeloma (MM), notably those with translocation t(11;14). Dexamethasone (d) has shown to enhance the expression of BCL-2 and pro-…
Videos
Background: Comorbidities and other patient factors in multiple myeloma (MM) can affect treatment decision making. While chemotherapy selection for MM in Medicare populations is different between blacks and non-blacks, including decreased use of bortezomib (BTZ) and hematopoietic…
Videos
click on the image above to watch the webcast
(to view the webcast in fullscreen, click on the bottom right square icon underneath the YouTube logo)
This video is the second in a five-part series that focuses on new strategies for multiple myeloma care. It was presented during the…
Videos
Is it possible for bone lesions to progress even when all other tests look good?
BOTTOM LINE:
In this week’s video, Dr. Durie discusses bone disease in myeloma patients and the importance of continued bone lesion monitoring.
Transcript:
This week’s “…
News Article
Los Angeles, CA, Dec. 4, 2019—The International Myeloma Foundation (IMF) announced today that four important research studies supported by the organization's Black Swan Research Initiative® (BSRI) to find a cure for multiple myeloma…
Event
Dr. Brian G.M. Durie discusses key takeaways from the annual conference and explains how this new and important information relates to myeloma patients, caregivers, and other members of the myeloma community.
Thursday January 9, 2020
4:00 pm Pacific/5:00 pm Mountain
6:00 pm Central/7:00 pm…
Event
Patients, caregivers, and doctors around the world can view the IMF's popular livestream IMWG Conference Series, "Making Sense of Treatment" from Orlando, FL. IMF Chairman Dr. Brian G.M. Durie, Dr. Maria V. Mateos, and IMF Chief Medical Officer Dr. Joseph Mikhael distill, debate, and discuss …
Event
Join us for this year’s International Myeloma Foundation and Clinical Care Options cosponsored symposium, where an esteemed panel of international experts will offer their perspectives on practice-changing data and optimal management of patients with myeloma.
Friday, December 6, 2019
1:00 PM ET…
Videos
In this week’s video, Dr. Durie explains what a "BEAT" is, and how it is similar to a BiTE.
BOTTOM LINE:
A BEAT is a bispecific antibody that binds T-cells to myeloma cells.
Transcript:
This week's "Ask Dr. Durie" comes from. A patient who wants to…
News Article
If you have been following what has been going on in Washington lately, you have likely heard a lot about government shutdowns and continuing resolutions (CRs). The federal government would have run out of funding on November 21st had Congress not acted. A short-term CR will temporarily fund the…
Videos
In this week’s video, Dr. Durie discusses the importance of resilience when overcoming the challenges that come with a myeloma diagnosis, and the support available to you.
BOTTOM LINE:
Maintaining one’s resilience when facing the challenges of a myeloma diagnosis is…
News Article
On October 15, 2019, the International Myeloma Foundation’s Advocacy Team hosted the first-ever “All Cancers Congress” at the National Press Club in Washington, D.C..
The event gave the cancer advocacy community a chance to discuss their individual advocacy…
Page
The International Myeloma Foundation brings myeloma support group leaders and patients to the annual meeting of the American Society of Hematology (ASH), an exciting convergence of over 30,000 health care professionals from around the world. Start following the IMF ASH team members now on social…
News Article
This year, the International Myeloma Foundation (IMF) has received the highest 4-star rating for the 15th time from Charity Navigator, the largest independent charity evaluator in the U.S.
Michael Thatcher, Charity Navigator President and CEO, stated, “Attaining a 4-star rating…
News Article
On September 26, 2019, the Food and Drug Administration approved daratumumab (DARZALEX, Janssen) for adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT).